Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer)

Expert Opinion on Biological Therapy

Volumn 9, Issue 2, 2009, Pages 187-200

  Schütte, Daniela ^a   Pluschke, Gerd ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Buruli ulcer; Chemotherapy; Mycobacterium ulcerans infection; Mycolactone

Indexed keywords

CLARITHROMYCIN; LACTONE DERIVATIVE; MACROLIDE; MOXIFLOXACIN; MYCOLACTONE B; NITRITE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; B LYMPHOCYTE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BURULI ULCER; CELLULAR IMMUNITY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG STRUCTURE; GRANULOMA; HEAT; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; HYPERBARIC OXYGEN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATION; MYCOBACTERIUM ULCERANS; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; REVIEW; SKIN TRANSPLANTATION; T LYMPHOCYTE; TH1 CELL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANIMAL; DISEASE MODEL; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOGENICITY; PATHOLOGY; VIRULENCE;

CORYNEBACTERINEAE; MYCOBACTERIUM ULCERANS;

ANIMALS; ANTITUBERCULAR AGENTS; BURULI ULCER; DISEASE MODELS, ANIMAL; HUMANS; MYCOBACTERIUM ULCERANS; VIRULENCE;

EID: 66149157915     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802631854     Document Type: Review

References (103)

1. Cook A. Mengo hospital notes, 1897, Makerere Medical School Library. BMJ 1970;2:378-379
2. Alsop DG. The Bairnsdale ulcer. Aust NZ J Surg 1972;41:317-319
3. MacCallum PTJC, Buckle G, Sissons HA. A new mycobacterial infection in man. J Pathol Bacteriol 1948;60:92-122
4. Asiedu K, Wansbrough-Jones M. Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies. Med J Aust 2007;186:55-56 (Pubitemid 46178814)
5. WHO. Buruli ulcer disease. Mycobacterium ulcerans infection: an overview of reported cases globally. Wkly Epidemiol Rec 2004;79:194-200
6. Debacker M, Aguiar J, Steunou C, et al. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 2004;10:1391-1398
7. Marston BJ, Diallo MO, Horsburgh CR Jr, et al. Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. Am J Trop Med Hyg 1995;52:219-224
8. Amofah G, Bonsu F, Tetteh C, et al. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 2002;8:167-170 (Pubitemid 34202439)
9. Kanga JM, Kacou ED, Kouame K, et al. [Buruli ulcer: epidemiological, clinical and therapeutic aspects in the Ivory Coast]. Med Trop (Mars) 2004;64:238-242
10. Brou T, Broutin H, Elguero E, et al. Landscape Diversity Related to Buruli Ulcer Disease in Cote d'Ivoire. PLoS Negl Trop Dis 2008;2:e271
11. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999;354:1013-1018 (Pubitemid 29438417)
12. Johnson PD, Stinear TP, Hayman JA. Mycobacterium ulcerans - a mini-review. J Med Microbiol 1999;48:511-513 (Pubitemid 29476454)
13. Stienstra Y, van der Graaf WT, te Meerman GJ, et al. Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health 2001;6:554-562
14. Meyers WM, Shelly WM, Connor DH, Meyers EK. Human Mycobacterium ulcerans infections developing at sites of trauma to skin. Am J Trop Med Hyg 1974;23:919-923
15. Marsollier L, Brodin P, Jackson M, et al. Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog 2007;3:e62 (Pubitemid 46827943)
16. Portaels F, Meyers WM, Ablordey A, et al. First Cultivation and Characterization of Mycobacterium ulcerans from the Environment. PLoS Negl Trop Dis 2008;2:e178 (Pubitemid 352002936)
17. Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 2002;68:4623-4628 (Pubitemid 34988148)
18. Portaels F, Elsen P, Guimaraes-Peres A, et al. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 1999;353:986 (Pubitemid 29132618)
19. Johnson PD, Hayman JA, Quek TY, et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007;186:64-68 (Pubitemid 46178817)
20. Benbow ME, Williamson H, Kimbirauskas R, et al. Aquatic invertebrates as unlikely vectors of Buruli ulcer disease. Emerg Infect Dis 2008;14:1247-1254
21. Buruli ulcer: progress report, 2004-2008. Wkly Epidemiol Rec 2008;83:145-154
22. Portaels F, Chemlal K, Elsen P, et al. Mycobacterium ulcerans in wild animals. Rev Sci Tech 2001;20:252-264 (Pubitemid 33585267)
23. Elsner L, Wayne J, O'Brien CR, et al. Localised Mycobacterium ulcerans infection in a cat in Australia. J Feline Med Surg 2008
24. Goto M, Nakanaga K, Aung T, et al. Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer. Am J Pathol 2006;168:805-811 (Pubitemid 43327733)
25. Eddyani M, Portaels F. Survival of Mycobacterium ulcerans at 37 degrees C. Clin Microbiol Infect 2007;13:1033-1035
26. Asiedu K, Scherpbier RW, Raviglione M. Buruli ulcer. Geneva: WHO;2000. Available from: http://whqlibdocwhoint/hq/2000/WHO-CDS-CPE-GBUI-20001pdf
27. Hayman J. Clinical features of Mycobacterium ulcerans infection. Australas J Dermatol 1985;26:67-73 (Pubitemid 16255392)
28. Portaels F, Aguiar J, Debacker M, et al. Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol 2002;9:1389-1391 (Pubitemid 35283312)
29. Thangaraj HS, Phillips RO, Evans MR, Wansbrough-Jones MH. Emerging aspects of Buruli ulcer. Expert Rev Anti Infect Ther 2003;1:217-222 (Pubitemid 38855085)
30. Rondini S, Kaser M, Stinear T, et al. Ongoing genome reduction in Mycobacterium ulcerans. Emerg Infect Dis 2007;13:1008-1015 (Pubitemid 47048072)
31. Kaser M, Rondini S, Naegeli M, et al. Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. BMC Evol Biol 2007;7:177 (Pubitemid 350199500)
32. Teelken MA, Stienstra Y, Ellen DE, et al. Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop 2003;88:51-56 (Pubitemid 37013336)
33. Debacker M, Aguiar J, Steunou C, et al. Buruli ulcer recurrence, Benin. Emerg Infect Dis 2005;11:584-589 (Pubitemid 40462909)
34. Amofah G, Asamoah S, Afram-Gyening C. Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop Doct 1998;28:81-83 (Pubitemid 28186609)
35. O'Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007;186:58-61 (Pubitemid 46178815)
36. Rondini S, Mensah-Quainoo E, Junghanss T, Pluschke G. What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us? J Clin Microbiol 2006;44:4273-4275
37. WHO. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization, Geneva, Switzerland; 2004
38. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005;49:3182-3186 (Pubitemid 41060558)
39. Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007;51:4029-4035 (Pubitemid 350057802)
40. Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis 2006;6:288-296
41. Bentoucha A, Robert J, Dega H, et al. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2001;45:3109-3112 (Pubitemid 32988836)
42. Ji B, Lefrancois S, Robert J, et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 2006;50:1921-1926
43. Dega H, Robert J, Bonnafous P, et al. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2000;44:2367-2372 (Pubitemid 30650881)
44. Ji B, Chauffour A, Robert J, et al. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2007;51:3737-3739 (Pubitemid 47519368)
45. Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg 1974;23:924-929
46. Haydel SE, Remenih CM, Williams LB. Broad-spectrum in vitro antibacterial activities of clay minerals against antibiotic-susceptible and antibiotic-resistant bacterial pathogens. J Antimicrob Chemother 2007
47. Phillips R, Adjei O, Lucas S, et al. Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides. Antimicrob Agents Chemother 2004;48:2866-2870 (Pubitemid 38989148)
48. Krieg RE, Wolcott JH, Confer A. Treatment of Mycobacterium ulcerans infection by hyperbaric oxygenation. Aviat Space Environ Med 1975;46:1241-1245
49. Efem SE. Clinical observations on the wound healing properties of honey. Br J Surg 1988;75:679-681 (Pubitemid 18177489)
50. Stinear TP, Seemann T, Pidot S, et al. Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res 2007;17:192-200 (Pubitemid 46220764)
51. Stinear TP, Mve-Obiang A, Small PL, et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 2004;101:1345-1349 (Pubitemid 38182691)
52. Huber CA, Ruf MT, Pluschke G, Kaser M. Multiple Loss of Immunogenic Proteins in Mycobacterium ulcerans Suggests Immune Evasion. Clin Vaccine Immunol 2008
53. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999;283:854-857 (Pubitemid 129501127)
54. Snyder DS, Small PL. Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog 2003;34:91-101 (Pubitemid 36297044)
55. Song F, Fidanze S, Benowitz AB, Kishi Y. Total synthesis of the mycolactones. Org Lett 2002;4:647-650
56. Fidanze S, Song F, Szlosek-Pinaud M, et al. Complete structure of the mycolactones. J Am Chem Soc 2001;123:10117-10118 (Pubitemid 32959624)
57. Mve-Obiang A, Lee RE, Portaels F, Small PL. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 2003;71:774-783 (Pubitemid 36150771)
58. Mve-Obiang A, Lee RE, Umstot ES, et al. A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin. Infect Immun 2005;73:3307-3312 (Pubitemid 40745871)
59. Ranger BS, Mahrous EA, Mosi L, et al. Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F. Infect Immun 2006;74:6037-6045 (Pubitemid 44657381)
60. Hong H, Demangel C, Pidot SJ, et al. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 2008;25:447-454 (Pubitemid 351725317)
61. Adusumilli S, Mve-Obiang A, Sparer T, et al. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo Cell Microbiol 2005;7:1295-1304
62. Coutanceau E, Marsollier L, Brosch R, et al. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 2005;7:1187-1196 (Pubitemid 41030943)
63. Coutanceau E, Decalf J, Martino A, et al. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 2007;204:1395-1403 (Pubitemid 46919877)
64. Pahlevan AA, Wright DJ, Andrews C, et al. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 1999;163:3928-3935 (Pubitemid 29450921)
65. Dobos KM, Small PL, Deslauriers M, et al. Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun 2001;69:7182-7186 (Pubitemid 32995484)
66. Torrado E, Adusumilli S, Fraga AG, et al. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 2007;75:3979-3988 (Pubitemid 47206296)
67. Oliveira MS, Fraga AG, Torrado E, et al. Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 2005;73:6299-6310
68. George KM, Pascopella L, Welty DM, Small PL. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 2000;68:877-883 (Pubitemid 30056548)
69. Hong H, Coutanceau E, Leclerc M, et al. Mycolactone Diffuses from Mycobacterium ulcerans-Infected Tissues and Targets Mononuclear Cells in Peripheral Blood and Lymphoid Organs. PLoS Negl Trop Dis 2008;2:e325
70. Hayman J. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol 1993;46:5-9 (Pubitemid 23039578)
71. Portaels F, Johnson P, Meyers WM. Buruli ulcer: diagnosis of Mycobacterium ulcerans disease. World Health Organization, Geneva, Switzerland;2001
72. Hayman J, McQueen A. The pathology of Mycobacterium ulcerans infection. Pathology 1985;17:594-600 (Pubitemid 16206726)
73. Rondini S, Horsfield C, Mensah-Quainoo E, et al. Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol 2006;208:119-128 (Pubitemid 43032993)
74. Guarner J, Bartlett J, Whitney EA, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 2003;9:651-656 (Pubitemid 36676359)
75. Dobos KM, Spotts EA, Marston BJ, et al. Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis 2000;6:158-164 (Pubitemid 30226893)
76. Okenu DM, Ofielu LO, Easley KA, et al. Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic. Clin Diagn Lab Immunol 2004;11:387-391 (Pubitemid 38380822)
77. Diaz D, Dobeli H, Yeboah-Manu D, et al. Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol 2006;13:1314-1321 (Pubitemid 46086896)
78. Revill WD, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 1973;2:873-877
79. Gooding TM, Johnson PD, Smith M, et al. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 2002;70:5562-5567 (Pubitemid 35050991)
80. Stanford JL, Revill WD, Gunthorpe WJ, Grange JM. The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Lond) 1975;74:7-16
81. Prevot G, Bourreau E, Pascalis H, et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 2004;72:958-965 (Pubitemid 38166676)
82. Westenbrink BD, Stienstra Y, Huitema MG, et al. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 2005;12:125-129
83. Schipper HS, Rutgers B, Huitema MG, et al. Systemic and local interferon-gamma production following Mycobacterium ulcerans infection. Clin Exp Immunol 2007;150:451-459 (Pubitemid 350098730)
84. Phillips R, Horsfield C, Kuijper S, et al. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol 2006;13:253-257 (Pubitemid 43383795)
85. Gooding TM, Kemp AS, Robins-Browne RM, et al. Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 2003;36:1076-1077 (Pubitemid 36513296)
86. Hirsch CS, Toossi Z, Othieno C, et al. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 1999;180:2069-2073
87. Torres M, Herrera T, Villareal H, et al. Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30-kilodalton antigen of Mycobacterium tuberculosis. Infect Immun 1998;66:176-180 (Pubitemid 28018817)
88. Jo EK, Park JK, Dockrell HM. Dynamics of cytokine generation in patients with active pulmonary tuberculosis. Curr Opin Infect Dis 2003;16:205-210 (Pubitemid 36677313)
89. Onwubalili JK, Scott GM, Robinson JA. Deficient immune interferon production in tuberculosis. Clin Exp Immunol 1985;59:405-413 (Pubitemid 15174433)
90. Fortune SM, Solache A, Jaeger A, et al. Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and-independent mechanisms. J Immunol 2004;172:6272-6280 (Pubitemid 38621234)
91. Pai M, Kalantri S, Menzies D. Discordance between tuberculin skin test and interferon-gamma assays. Int J Tuberc Lung Dis 2006;10:942-943 (Pubitemid 44197858)
92. Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, et al. Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 2006;79:1150-1156 (Pubitemid 44835548)
93. Bejon P, Mwacharo J, Kai O, et al. The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol 2007;179:4193-4201
94. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 1996;173:269-272 (Pubitemid 26006833)
95. Nookala S, Srinivasan S, Kaliraj P, et al. Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis. Infect Immun 2004;72:2598-2604 (Pubitemid 38542386)
96. Malhotra I, Mungai P, Wamachi A, et al. Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 1999;162:6843-6848 (Pubitemid 29309413)
97. Liebeschuetz S, Bamber S, Ewer K, et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004;364:2196-2203 (Pubitemid 40018449)
98. Schutte D, Um-Boock A, Mensah-Quainoo E, et al. Development of highly organized lymphoid structures in buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 2007;1:e2 (Pubitemid 352024662)
99. Torrado E, Fraga AG, Castro AG, et al. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 2007;75:977-987 (Pubitemid 46203463)
100. Kiszewski AE, Becerril E, Aguilar LD, et al. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 2006;143:445-451
101. Phillips R, Horsfield C, Mangan J, et al. Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. Infect Immun 2006;74:2917-2924 (Pubitemid 43673002)
102. Peduzzi E, Groeper C, Schutte D, et al. Local activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol 2007;127:638-645 (Pubitemid 46271032)
103. Devitt A, Pierce S, Oldreive C, et al. CD14-dependent clearance of apoptotic cells by human macrophages: the role of phosphatidylserine. Cell Death Differ 2003;10:371-382 (Pubitemid 36582375)